伐尼克兰
安非他酮
重性抑郁障碍
戒烟
尼古丁贴片
医学
安慰剂
尼古丁替代疗法
不利影响
尼古丁
药物治疗
随机对照试验
内科学
精神科
心情
替代医学
病理
作者
Paul M. Cinciripini,George Kypriotakis,Charles Green,David Lawrence,Robert M. Anthenelli,Jennifer A. Minnix,Janice A. Blalock,Diane Beneventi,Chad Morris,Maher Karam‐Hage
摘要
Improving treatment outcomes for smokers with major depressive disorder (MDD) can have significant public health implications.To evaluate the safety and efficacy of smoking cessation pharmacotherapy among smokers with MDD.Secondary analysis of a randomized, double-blind, active- (nicotine patch) and placebo-controlled trial of 12 weeks of either varenicline or bupropion with a 12-week follow-up.Community volunteers 18-75 years of age; smoke 10+ cigarettes/day; with clinically stable MDD (N = 2635) or no psychiatric disorder (N = 4028), from 140 sites in 16 countries.Twelve weeks of pharmacotherapy (placebo [PLA], nicotine replacement therapy [NRT], bupropion [BUP], varenicline [VAR]) plus brief cessation counseling.Primary safety outcome: the occurrence of ≥1 treatment-emergent, moderate to severe neuropsychiatric adverse event (NPSAE). Primary efficacy outcome: biochemically confirmed continuous abstinence (CA) during the final 4 weeks of treatment (Weeks 9-12).A total of 6653 participants (56% female; 39% MDD) ~47 years old. Risk of NPSAEs did not differ by medication for MDD. MDD had higher risk (p < .0001) for NPSAEs than the NPC. Efficacy (6653; intent-to-treat): CA rates for MDD versus NPC respectively were 31.2% versus 38.0% VAR; 23.0% versus 26.1% BUP; 22.6% versus 26.4% NRT; and 13.4% versus 13.7% PLA but no differential treatment effect was noted within the cohorts. All active treatments differed from PLA but VAR showed the largest effect.Results suggest that for MDD smokers, inclusive of those with recurrent episode, varenicline plus counseling may be the best pharmacological option for the treatment of smoking given its greater efficacy effect size and similar risk of NPSAEs.ClinicalTrials.gov Identifier: NCT01456936. https://clinicaltrials.gov/ct2/show/NCT01456936.
科研通智能强力驱动
Strongly Powered by AbleSci AI